Siegfried expands US footprint with major acquisition of Noramco & Extractas Bioscience
The deal brings three high-quality small-molecule drug substance sites into Siegfried’s portfolio
The deal brings three high-quality small-molecule drug substance sites into Siegfried’s portfolio
Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites
In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
The deal accelerates GE HealthCare’s digital transformation, expanding its reach into outpatient care and enterprise imaging—a $2 billion-plus growth market
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
Subscribe To Our Newsletter & Stay Updated